<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03597256</url>
  </required_header>
  <id_info>
    <org_study_id>43CH1627</org_study_id>
    <nct_id>NCT03597256</nct_id>
  </id_info>
  <brief_title>Restylane Defyne for Correction of Chin Retrusion</brief_title>
  <official_title>A Randomized, Multi-center, Evaluator-blinded, No-treatment Controlled Study to Evaluate the Effectiveness and Safety of Restylane Defyne for Correction of Chin Retrusion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Q-Med AB</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Q-Med AB</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, evaluator-blinded, no-treatment controlled study in subjects with Chin
      Retrusion.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 8, 2018</start_date>
  <completion_date type="Anticipated">July 2020</completion_date>
  <primary_completion_date type="Actual">September 24, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>GCRS(Galderma Chin Retrusion Scale) at 6 months</measure>
    <time_frame>6 month</time_frame>
    <description>1 point improvement from baseline on the GCRS as measured by the Blinded Evaluator at 6 months (after last treatment in Treatment Group, and after randomization in Control Group)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">148</enrollment>
  <condition>Chin Retrusion</condition>
  <arm_group>
    <arm_group_label>Treatment Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single injection and optional touch-up injection with Restylane Defyne in chin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Restylane Defyne</intervention_name>
    <description>Intradermal injection</description>
    <arm_group_label>Treatment Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Signed and dated informed consent to participate in the study.

          2. Men or women aged 18 years of age or older of Chinese origin.

          3. Subjects seeking augmentation therapy for chin retrusion.

          4. GCRS score of 1 or 2 as assessed by the Blinded Evaluator

        Exclusion Criteria:

          1. Known/previous allergy or hypersensitivity to any injectable hyaluronic acid gel.

          2. Known/previous allergy or hypersensitivity to local anaesthetics, e.g. lidocaine or
             other amide-type anaesthetics.

          3. History of severe or multiple allergies, manifested by anaphylaxis.

          4. Previous facial surgery, or tissue revitalization treatment with laser or light,
             needling, mesotherapy, radiofrequency, ultrasound, cryotherapy, chemical peeling or
             dermabrasion below the level of the horizontal line from subnasale within 6 months
             before treatment.

          5. Previous surgery (including aesthetic facial surgical therapy or liposuction),
             piercing or tattoo in the area to be treated.

          6. Previous tissue augmentation therapy or contouring with any permanent
             (non-biodegradable) or semi-permanent filler, autologous fat, lifting threads or
             permanent implant below the level of the horizontal line from subnasale.

          7. Other condition preventing the subject from entering the study in the Investigator's
             opinion, e.g. subjects not likely to avoid other facial cosmetic treatments, subjects
             anticipated to be unreliable, unavailable or incapable of understanding the study
             assessments or having unrealistic expectations of the treatment result.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>QmedAB</last_name>
    <phone>+86 21-23159666</phone>
    <email>Q-Med@galderma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Q-Med AB</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Q-Med AB</last_name>
      <phone>021-23159666</phone>
      <email>Q-Med@galderma.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>July 13, 2018</study_first_submitted>
  <study_first_submitted_qc>July 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 24, 2018</study_first_posted>
  <last_update_submitted>October 15, 2019</last_update_submitted>
  <last_update_submitted_qc>October 15, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 16, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hyaluronic acid</keyword>
  <keyword>Chin Retrusion</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

